Company Description
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure.
Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.
The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021.
Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Country | United States |
Founded | 1999 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 59 |
CEO | Nestor Jaramillo |
Contact Details
Address: 12988 Valley View Road Eden Prairie, Minnesota 55344 United States | |
Phone | 952 345 4200 |
Website | nuwellis.com |
Stock Details
Ticker Symbol | NUWE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001506492 |
CUSIP Number | 12542Q706 |
ISIN Number | US67113Y4052 |
Employer ID | 68-0533453 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Nestor Jaramillo Jr. | President, Chief Executive Officer and Director |
Robert B. Scott | Chief Financial Officer |
Neil P. Ayotte Esq. | Senior Vice President, General Counsel, Secretary and Chief Compliance Officer |
John Kowalczyk | Senior Vice President of Sales and Marketing |
Sandra Eayrs | Chief Human Resources Officer |
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. | Chief Medical Officer and Member of Medical Advisory Board |
Paul Wotta | Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 20, 2024 | D | Notice of Exempt Offering of Securities |
Nov 15, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 12, 2024 | 8-K | Current Report |
Nov 7, 2024 | 8-K | Current Report |
Nov 1, 2024 | 8-K | Current Report |
Oct 23, 2024 | 8-K | Current Report |
Sep 6, 2024 | EFFECT | Notice of Effectiveness |
Sep 6, 2024 | 424B3 | Prospectus |
Sep 4, 2024 | D | Notice of Exempt Offering of Securities |